摘要
近年来,多种研究表明CXCL12/CXCR7趋化轴在肿瘤的发生、发展及演变过程中发挥着重要作用,CXCL12/CXCR7趋化轴能促进肿瘤细胞的生长和增殖,增强肿瘤细胞的黏附能力和促进肿瘤新生血管的生成,参与肿瘤细胞的转移过程。趋化因子受体CXCR7作为趋化因子CXCL12的第二受体,在肿瘤的进展过程中发挥着重要作用,CXCL12/CXCR7趋化轴有望成为肿瘤分子靶向治疗的新途径。
In recent years, various studies have shown that CXCL12/CXCR7 chemotactic axis plays an im-portant role in the occurrence, development and evolution of tumors. CXCL12/CXCR7 chemotactic axis can promote the growth and proliferation of tumor cells, enhance the adhesion ability of tumor cells and promote the generation of tumor neovascularization, and participate in the metastasis of tumor cells. CXCR7, as the second receptor of CXCL12, plays an important role in the progression of tumors. The CXCL12/CXCR7 chemotactic axis is expected to become a new way for tumor molecular targeted therapy.
出处
《临床医学进展》
2021年第3期1193-1198,共6页
Advances in Clinical Medicine
